AdipoGen Life Sciences

Monosodium urate (ready-to-use)

As low as CHF 490.00
In stock
Only %1 left
AG-CR1-3951-M01010 mgCHF 490.00

Specifications / Handling

More Information
Product Details
Synonyms MSU (ready-to-use); Uric acid (ready-to-use)
Product Type Chemical
Properties
Formula

C5H3N4O3 . Na

MW 167.1 . 23.0
CAS 1198-77-2
RTECS YU7062000
Appearance Liquid. Solution may appear as a slightly hazy suspension.
Formulation In PBS.
Concentration 20 mg/ml.
Endotoxin Content <0.001EU/μg purified protein (LAL test; Lonza).
Other Product Data

Note: Be sure to tap vials before opening to recover all liquid.

InChi Key NAFSTSRULRIERK-UHFFFAOYSA-M
Smiles [Na+].[O-]C1=NC(=O)NC2=C1NC(=O)N2
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Vortex before use.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Documents
Protocols Download PDF Download PDF
MSDS Download PDF Download PDF
Product Specification Sheet
Datasheet Download PDF Download PDF

Scientific Background Information

Product Description
  • NLRP3/NALP3 inflammasome activator. Specially crystallized and tested for biological activity.
  • Stimulates the caspase-1 activating NLRP3/NALP3 inflammasome, resulting in the production of active IL-1β and IL-18.
Product-specific References
  1. Gout-associated uric acid crystals activate the NALP3 inflammasome: F. Martinon, et al.; Nature 440, 237 (2006) [PMID: 16407889]
  2. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases: M.T. Shio, et al.; PLoS Pathog. 5, e1000559 (2009) [PMC2722371]
  3. Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process: E.J. Giamarellos-Bourboulis, et al.; Ann. Rheum. Dis. 68, 273 (2009) [PMID: 18390571]
  4. Monosodium urate crystals in inflammation and immunity: Y. Shi, et al.; Immunol. Rev. 233, 203 (2010) [PMID: 20193001]
  5. Calcium phosphate particles stimulate interleukin-1β release from human vascular smooth muscle cells: A role for spleen tyrosine kinase and exosome release: Y. Dautova, et al.; J. Mol. Cell Cardiol. 115, 82 (2018) [PMC5823844]
  6. Cutting Edge: G Protein Subunit β 1 Negatively Regulates NLRP3 Inflammasome Activation: T. Murakami, et al.; J. Immunol. 202, 1942 (2019) [PMID: 30777924]
  7. Expression of a PYCARD/ASC variant lacking exon 2 in Japanese patients with palindromic rheumatism increases interleukin-1β secretion: Y. Suganuma, et al.; Asian Pac. J. Allergy Immunol. 40, 81 (2019) [PMID: 31421660]
  8. Urolithin A suppresses NLRP3 inflammasome activation by inhibiting the generation of reactive oxygen species and prevents monosodium urate crystal-induced peritonitis: W. Komatsu, et al. Biosci., Biotech., Biochem. 88, 966 (2024) [PMID: 38772744]

    Additional References using AdipoGen AG-CR1-3950/AG-CR1-3951:
  9. RIP3-mediated necrotic cell death accelerates systematic inflammation and mortality: L. Meng, et al.; PNAS 112, 11007 (2015) [PMC4568286]
  10. IL-1 beta but not the NALP3 inflammasome is an important determinant of endothelial cell responses to necrotic/dangerous trophoblastic debris: J. Wei, et al.; Placenta 36, 1385 (2015) [PMID: 26515928]
  11. Shigella hijacks the glomulin-cIAPs-inflammasome axis to promote inflammation: S. Suzuki, et al.; EMBO Rep.19, 89 (2018) [PMC5757219]
  12. Optimized protocols for studying the NLRP3 inflammasome and assessment of potential targets of CP-453,773 in undifferentiated THP1 cells: J.A. Guzova, et al.; J. Immunol. Methods 467, 19 (2019) [PMID: 30735689]
  13. L-plastin enhances NLRP3 inflammasome assembly and bleomycin-induced lung fibrosis: H. Joshi, et al.; Cell Rep. 38, 110507 (2022) [PMC8998782]
  14. SERTAD1 initiates NLRP3-mediated inflammasome activation through restricting NLRP3 polyubiquitination: J. Ha, et al.; Cell Rep. 43, 113752 (2024) [PMID: 38341852]
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.